B-Cell Lymphoma ML43389

Study #ML43389

An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies.


B-Cell Lymphoma ML43389 will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin’s lymphoma [NHL]).

Sponsor: Genentech, Inc.

Principal Investigator: Dr. Tara Graff

Email Us About This Trial

Back To Clinical Trials NCI Database Entry